M. Hodges

发表

Treatment of HCV infection by targeting microRNA.

S. Kauppinen, S. Zeuzem, H. Janssen, 2013, The New England journal of medicine.

In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122

L. van Doorn, T. Parsley, A. Patick, 2014, Antimicrobial Agents and Chemotherapy.

MicroRNA‐122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection

H. Tillmann, K. Patel, M. Hodges, 2015, Journal of medical virology.

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

C. Viscoli, Jm Brown, M. Hodges, 2005, The Lancet.

Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial.

A. Levin, M. Moerland, A. Cohen, 2015, British journal of clinical pharmacology.

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

J. Perfect, T. Walsh, I. Lutsar, 2002, The Pediatric infectious disease journal.

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.

W. Kreisel, G. Carosi, M. Hodges, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

First-in-Human Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

M. Hodges, K. Shaw, R. Mansbach, 2017 .

Phase 1 Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001 and to Investigate the Effect of Food on APX001 Bioavailability

M. Hodges, K. Shaw, R. Mansbach, 2017 .

Absorption, Distribution, and Excretion of 14C-APX001 after Single-Dose Administration to Rats and Monkeys

M. Hodges, K. Shaw, M. E. Fitzsimmons, 2017, Open Forum Infectious Diseases.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Richard Sylvester, Raoul Herbrecht, John E Bennett, 2002, The New England journal of medicine.

Safety of voriconazole and dose individualization.

N. Wood, I. Lutsar, M. Hodges, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and Pharmacokinetics of Fosmanogepix (APX001) in the Treatment of Candida Endophthalmitis and Hematogenous Meningoencephalitis in Nonneutropenic Rabbits

M. Finkelman, T. Walsh, M. Hodges, 2020, Antimicrobial Agents and Chemotherapy.

Quantitative Systems Pharmacology Model of hUGT1A1‐modRNA Encoding for the UGT1A1 Enzyme to Treat Crigler‐Najjar Syndrome Type 1

J. Burke, M. Hodges, Pratap Singh, 2018, CPT: pharmacometrics & systems pharmacology.

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.

S. Zeuzem, H. Janssen, V. Kupčová, 2014, Antiviral research.

Inducing Hepatitis C Virus Resistance After Pig Liver Transplantation—A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion

H. Janssen, N. Selzner, R. Persson, 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

HCV infection and miravirsen.

S. Kauppinen, H. Janssen, M. Hodges, 2013, The New England journal of medicine.

Clinical Efficacy and Safety of a Novel Antifungal, Fosmanogepix, in Patients with Candidemia Caused by Candida auris: Results from a Phase 2 Trial

K. Boffard, M. Hodges, M. Tawadrous, 2023, Antimicrobial agents and chemotherapy.

Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.

A. Levin, M. Moerland, J. Weening, 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial

G. Rahav, R. Ferrer, B. Kullberg, 2020 .

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION

S. Zeuzem, H. Janssen, A. Levin, 2012 .

1202 SEQUENCE ANALYSIS OF HCV VARIANTS FROM A PHASE IIA TRIAL OF MIRAVIRSEN (MIR), AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT NAIVE PATIENTS WITH CHRONIC HCV INFECTION

A. Patick, M. Hodges, K. Zeh, 2012 .

1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial

G. Rahav, B. Kullberg, M. Hodges, 2020 .

Letters to the Editor Multidrug-Resistant Trichosporon asahii Isolates Are Susceptible to Voriconazole

R. Rubin, D. Denning, J. Wingard, 2003 .

Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers

M. Hodges, K. Shaw, M. Tawadrous, 2023, Antimicrobial agents and chemotherapy.

Treatment of HCV infection by targeting microRNA.

S. Kauppinen, S. Zeuzem, H. Janssen, 2013, The New England journal of medicine.

Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial

G. Rahav, R. Ferrer, M. Hodges, 2023, The Journal of antimicrobial chemotherapy.